MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fmed.2026.1751155

Медицинская библиотека · Frontiers in medicine · 2026

A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system.

Zhao Xue, Sun Xiutian, Ma Meng, Teng Lijuan, Qu Xiaohua

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Pediatric drug-induced hyperglycemia/diabetes mellitus (DIH/DIDM) is regarded as a preventable iatrogenic condition; nevertheless, its clinical under-recognition persists, and age-specific pharmacovigilance evidence remains critically deficient. This study conducted a retrospective pharmacovigilance investigation to identify risk signals associated with pediatric DIH/DIDM.

RESEARCH DESIGN AND

METHODS

We extracted pediatric (age < 18 years) adverse-event reports from the FDA Adverse Event Reporting System (2004 Q1-2025 Q1) and retained those mapped to any of nine predefined MedDRA Preferred Terms (PTs) for hyperglycemia or diabetes mellitus. A disproportionality analysis was subsequently performed to estimate the reporting association between suspect drugs and the events of interest.

RESULTS

We mined 504,458 pediatric adverse-event reports from the U.S. FDA Adverse Event Reporting System (2004Q1-2025Q1) and detected 195 positive drug-adverse event signals. Among 2,436 pediatric DIH/DIDM cases, 72% were adolescents aged 10-18 years; the overall median age was 13 years (IQR 9-16). Antineoplastic agents, glucocorticoids, immunosuppressants, psychotropic medications, and growth hormone constituted five cardinal risk clusters, and Off-label signals for drugs-including minocycline and montelukast-were captured for the first time. Underlying conditions were predominantly acute lymphoblastic leukemia, neuropsychiatric disorders, immunosuppression-related disorders, and growth hormone deficiency.

CONCLUSION

Our study systematically delineated the risk signals implicated in pediatric DIH/DIDM. Clinicians should heighten surveillance when prescribing potentially diabetogenic agents and pay particular attention to age-related windows of susceptibility.

Для цитирования: Zhao Xue, Sun Xiutian, Ma Meng, Teng Lijuan, Qu Xiaohua. A real-world investigation of drug-induced hyperglycemia and diabetes mellitus in pediatric populations using the FDA adverse event reporting system.. Frontiers in medicine. 2026. DOI: 10.3389/fmed.2026.1751155.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.